Quarterly ResultAug 11, 2026, 04:15 PM
Gain Therapeutics Q2 Net Loss $4.68M; FDA OKs Phase 2 Rexaceract
AI Summary
Gain Therapeutics reported a Q2 2026 net loss of $4.68 million, or $(0.11) per share, and a six-month net loss of $10.28 million, or $(0.24) per share. The company received FDA Investigational New Drug (IND) authorization to commence a Phase 2 study for its lead candidate, rexaceract, in Parkinson's disease, expected to begin in Q3 2026. Despite this clinical progress, the company issued a going concern warning, stating that its $13.1 million cash balance as of June 30, 2026, is insufficient to fund operations for the next 12 months.
Key Highlights
- FDA authorized Phase 2 study for rexaceract in Parkinson's disease, starting Q3 2026.
- Q2 2026 net loss was $4.68 million, or $(0.11) per share.
- Six-month 2026 net loss was $10.28 million, or $(0.24) per share.
- Cash and cash equivalents totaled $13.08 million as of June 30, 2026.
- Company issued a going concern warning, needing additional funding by Q2 2027.
- Net proceeds from ATM offering were $1.82 million for the six months ended June 30, 2026.
- Phase 1b study of rexaceract expected to complete Part 2 in October 2026.
Price Impact
More from GANX